With $130M, Protego pushes forward a new type of amyloidosis drug

The startup’s lead prospect stabilizes abnormal proteins in patients with amyloid “light chain” amyloidosis, an approach that ...
The Malaysian Reserve

Protego Biopharma Raises $130 Million Oversubscribed Series B Financing to Advance First-in-Class AL Amyloidosis Program into Pivotal Study

Financing led by Novartis Venture Fund and Forbion, with new investment from Omega Funds, Droia Ventures, YK Bioventures, and ...
Fierce Biotech

Protego plans pivotal trial for AL amyloidosis prospect with $130M series B

Protego Biopharma is gearing up to bring its amyloid light-chain (AL) amyloidosis prospect into pivotal testing using its new ...
Le Lézard

AT&T to Release Fourth-Quarter 2025 Earnings on Jan. 28

We will release our fourth-quarter 2025 results on Wednesday, Jan. 28, 2026, and webcast a conference call to discuss results.Key Takeaways:AT&T will release its fourth-quarter 2025 results on Jan.
Le Lézard

IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types

IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the clearance of an investigational new drug (IND) ...
The Manila Times

ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference

ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for ...
Mirage News

U of Study Uncovers New Mad Cow Disease Culprit

Groundbreaking research led by the University of Alberta challenges the belief that mad cow disease is caused only by ...